Why Definium Therapeutics (DFTX) Is Up 5.7% After Second Positive Phase 3 DT120 Anxiety Trial Result

Definium Therapeutics recently reported that its Phase 3 Panorama trial of DT120, an LSD-based orally disintegrating tablet, in adults with generalized anxiety disorder met the primary and all key secondary endpoints, with a single 100 µg dose delivering a statistically significant 5.1‑point placebo‑adjusted reduction in HAM‑A anxiety scores at Week 12. The data also showed early and durable symptom relief from just one treatment, with meaningful improvements as soon as Day 2 and no new...